title: Neuroimaging biomarkers for Parkinson disease: facts and fantasy.
abstract: In this grand rounds, we focus on development, validation, and application of neuroimaging biomarkers for Parkinson disease (PD). We cover whether such biomarkers can be used to identify presymptomatic individuals (probably yes), provide a measure of PD severity (in a limited fashion, but frequently done poorly), investigate pathophysiology of parkinsonian disorders (yes, if done carefully), play a role in differential diagnosis of parkinsonism (not well), and investigate pathology underlying cognitive impairment (yes, in conjunction with postmortem data). Along the way, we clarify several issues about definitions of biomarkers and surrogate endpoints. The goal of this lecture is to provide a basis for interpreting current literature and newly proposed clinical tools in PD. In the end, one should be able to critically distinguish fact from fantasy.
authors.affiliation: Departments of Neurology, Radiology, Anatomy & Neurobiology, Occupational Therapy, and Physical Therapy, Washington University, St Louis, MO.
authors.forename: Joel S
authors.initials: JS
authors.lastname: Perlmutter
authors.forename: Scott A
authors.initials: SA
authors.lastname: Norris
mesh_terms: D015415:Biomarkers / Q000378:metabolism; D001921:Brain / Q000378:metabolism / Q000473:pathology; D003072:Cognition Disorders / Q000175:diagnosis / Q000378:metabolism / Q000523:psychology; D003937:Diagnosis, Differential; D006801:Humans; D059906:Neuroimaging / Q000379:methods* / Q000592:standards; D010300:Parkinson Disease / Q000175:diagnosis* / Q000378:metabolism* / Q000523:psychology
chemical_list: D015415:Biomarkers